Panniculitis News and Research

RSS

First molecular biomarker for acquired generalized lipodystrophy discovered

Researchers at UT Southwestern Medical Center have discovered the first molecular biomarker for acquired generalized lipodystrophy (AGL), a rare disorder in which fat deposits are destroyed, causing patients to have dangerously low body fat, signs of accelerated aging, and severe metabolic diseases including diabetes and fatty liver.

21 Feb 2023

Two cases of acute abdominal pain in patients with COVID-19 in their second week of illness

Researchers described two cases of acute pain in the abdomen of patients with COVID-19.

17 Oct 2022

Scientists pinpoint TIM-3 protein as next potential target for immunotherapy treatments

Following the 2018 Nobel Prize for Medicine, global attention is now more than ever turned toward the promise of immunotherapy in oncology. An international team’s work has shed new light on a molecule called TIM-3 that might play a key role in the regulation of the immune response.

31 Oct 2018

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

Scientists identify genetic mutation that causes rare childhood disease

An international collaboration of scientists, including researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health, has identified a genetic mutation that causes a rare childhood disease characterized predominantly by inflammation and fat loss.

1 Nov 2011

Researchers identify blip in gene that causes JMP syndrome

UT Southwestern Medical Center researchers have identified a gene responsible for a rare disease that results in severe joint stiffness, muscle loss, anemia and panniculitis-induced lipodystrophy, or JMP syndrome.

2 Dec 2010

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois, as part of the ASCO proceedings.

21 May 2010